Overview
Also known as:
FDA & Trial Timeline
10 eventsMedical College of Wisconsin — PHASE2
Sun Yat-sen University — PHASE1, PHASE2
Danielle Wallace — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2
Merck Sharp & Dohme LLC — PHASE2
Fudan University — PHASE2
Hoffmann-La Roche — PHASE3
The First Affiliated Hospital of Soochow University — PHASE2
Merck Sharp & Dohme LLC — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Cytophagic histiocytic panniculitis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Cytophagic histiocytic panniculitis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Cytophagic histiocytic panniculitis.
Community
No community posts yet. Be the first to share your experience with Cytophagic histiocytic panniculitis.
Start the conversation →Latest news about Cytophagic histiocytic panniculitis
Disease timeline:
New recruiting trial: POLA-R-CHP in the First-line Treatment of Transformed DLBCL
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
New recruiting trial: Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
A new clinical trial is recruiting patients for Cytophagic histiocytic panniculitis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cytophagic histiocytic panniculitis
Which specialists treat Cytophagic histiocytic panniculitis?
17 specialists and care centers treating Cytophagic histiocytic panniculitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.